YousifAbubakrMD

PubMed

• The Next Step in Your Career: Getting the Right Opportunity and the Right Contract.
  Claire F. Verschraegen, Yousif Abubakr, Mark Lee> ;American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 2020 Mar 17
• 455 citations
  Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TR...
  Howard S. Hochster, Lowell L. Hart, Ramesh K. Ramanathan, Barrett H. Childs, John D. Hainsworth, Allen Lee Cohn, Lucas Wong, Louis Fehrenbacher, Yousif A. Abubakr, M. ...> ;Journal of Clinical Oncology. 2008 Jul 20
• 704 citations
  EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer
  Alberto Sobrero, Joan Maurel, Louis Fehrenbacher, Werner Scheithauer, Yousif A. Abubakr, Manfred P. Lutz, M. Eugenia Vega-Villegas, Cathy Eng, Ernst U. Steinhauer, Jan...> ;Journal of Clinical Oncology. 2008 May 10
• Cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): Safety analysis of 800 patients in a randomized phase III trial (EPIC).
  Abubakr Y, Eng C, Wong L, Pautret V, Scheithauer W, Maurel J, Kroening H, Lutz M, Zubel A, Sobrero A> ;J. Clin. Oncol.. 2006-06-20
• A phase I trial of [(1- 4)- linked b-D-mannopyranose]17 - [(1- 6)-linked-a-D- galactopyranose]10 (DAVANAT) co-administered with 5-fluorouracil, in patients with refrac...
  Fuloria J, Abubakr Y, Perez R, Pike M, Zalupski M> ;J. Clin. Oncol.. 2005-06-01
• Cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): Safety analysis of the first 400 patients in a randomized phase III trial (EPIC).
  Sobrero A, Scheithauer W, Maurel J, Mineur L, Fehrenbacher L, Kisker O, Kopit J, Langer C, Schlichting M, Abubakr Y> ;J. Clin. Oncol.. 2005-06-01
• 15 citations
  Bcl-2 antisense oligonucleotides are effective against systemic but not central nervous system disease in severe combined immunodeficient mice bearing human t(14;18) f...
  Ramzi M. Mohammad, Yousif A. Abubakr, Maria Dan, Amro Aboukameel, Christine S. Chow, Anwar N. Mohamed, Nayera Hamdy, Ayad Al-Katib> ;Clinical Cancer Research. 2002 Apr 1
• 4 citations
  The role of immunotherapy in urologic malignancies.
  Yousif A. Abubakr, Bruce G. Redman> ;Cancer Treatment and Research. 1996 Jan 1
• Establishment of a human B-CLL xenograft model: utility as a preclinical therapeutic model.
  Mohammad, R. M., Mohamed, A. N., Hamdan, M. Y., Vo, T., Chen, B., Katato, K., Abubakr, Y. A., Dugan, M. C., al-Katib, A.> ;Leukemia. 1996 Jan
• Antisense oligodeoxyribonucleotide down-regulation of bcl-2 gene expression inhibits growth of the low-grade non-Hodgkin's lymphoma cell line WSU-FSCCL.
  Smith, M. R., Abubakr, Y., Mohammad, R., Xie, T., Hamdan, M., al-Katib, A.> ;Cancer Gene Ther. 1995 Sep
• 18 citations
  Phase II trial of recombinant interleukin-1β in patients with metastatic renal cell carcinoma
  Bruce G. Redman, Yousif A. Abubakr, Ta-Hsu Chou, Peggy S. Esper, Lawrence E. Flaherty> ;Journal of Immunotherapy With Emphasis on Tumor Immunology. 1994 Oct 1
• 23 citations
  Spontaneous Remission of Renal Cell Carcinoma: A Case Report and Immunological Correlates
  Yousif A. Abubakr, Ta-Hsu Chou, Bruce G. Redman> ;The Journal of Urology. 1994 Jul 1
• Join now to see all